Why Is MIRA Pharmaceuticals Stock Gaining Tuesday?
MIRA Pharmaceuticals (NASDAQ: MIRA) stock jumps as MIRA-55 meets key preclinical study milestones for non-opioid inflammatory pain relief.
Stocks · News reference
MIRA Pharmaceuticals Says 7-Day Dose-Range Finding Toxicology Studies Of MIRA-55 In Rats And Dogs Completed, Supporting Next Phase Of IND-Enabling Program; Targets IND Submission In Q1 2027
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
MIRA Pharmaceuticals shares are trading higher after the company announced results from the completed 7-day dose-range finding toxicology and toxicokinetic studies of MIRA-55 in rats and dogs.
8-K filing — MIRA PHARMACEUTICALS, INC. (MIRA)
Filed: 2026-09-01 AccNo: 0001493152-26-040930 Size: 238 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits